Proteros and Hutchison MediPharma enter into long-term research collaboration agreement
Proteros Biostructures GmbH announced that they entered into a substantial research collaboration agreement with Hutchison MediPharma Limited (HMP), whereby Proteros will support HMP’s drug discovery process throughout 2011 and beyond.
Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP. This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.
Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Gene that improves quality of reprogrammed stem cells identified by Singapore scientists - Provides 'a better inkling of what we might aim for before differentiating iPS cells to clinically useful cell types'
Roche Applied Science and TIB Molbiol offer Assay Solution for Rapid EHEC Identification
PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Molecular 'firing squad' in mice triggered by overeating destroys metabolism
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Zero in on ozone with fluorescent solution that detects harmful molecule in air and body - Personal ozone detectors and biomedical indicators could result from a chemical probe that glows bright green when exposed to ozone
To-BBB and GSK to collaborate on brain delivery of a biologic product
